Amgen Grants Rights to Sell Anemia Drug in Greece

Amgen, the world’s largest biotechnology company, and Genesis Pharma S.A. have agreed to grant Genesis certain exclusive rights to distribute, market and sell Aranesp, Amgen’s anti-anemia drug, in Greece and Cyprus.

The U.S. Food and Drug Administration and the European Medicine Evaluation Agency are evaluating Aranesp for the treatment of anemia resulting from chronic renal failure.

“This agreement confirms Amgen’s commitment to expand its business in all European Union countries,” said Aart Brouwer, vice president for Amgen Europe.

“Genesis is a strong player in the Greek pharmaceutical market and has the reach and capabilities to bring this novel biotechnological medicine to the patients and their physicians,” he added.

Amgen’s headquarters is in Thousand Oaks.